Cargando…
510 Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Cystic Fibrosis Society.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527872/ http://dx.doi.org/10.1016/S1569-1993(22)01200-0 |
| _version_ | 1784801169720213504 |
|---|---|
| author | Thornton, C. Kalikin, L. Sanders, D. McClellan, S. LeBar, W. VanDevanter, D. Heltshe, S. Caverly, L. LiPuma, J. |
| author_facet | Thornton, C. Kalikin, L. Sanders, D. McClellan, S. LeBar, W. VanDevanter, D. Heltshe, S. Caverly, L. LiPuma, J. |
| author_sort | Thornton, C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9527872 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Cystic Fibrosis Society. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95278722022-10-03 510 Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study Thornton, C. Kalikin, L. Sanders, D. McClellan, S. LeBar, W. VanDevanter, D. Heltshe, S. Caverly, L. LiPuma, J. J Cyst Fibros Posters European Cystic Fibrosis Society. 2022-10 2022-10-03 /pmc/articles/PMC9527872/ http://dx.doi.org/10.1016/S1569-1993(22)01200-0 Text en Copyright © 2022 European Cystic Fibrosis Society. All rights reserved. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Posters Thornton, C. Kalikin, L. Sanders, D. McClellan, S. LeBar, W. VanDevanter, D. Heltshe, S. Caverly, L. LiPuma, J. 510 Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study |
| title | 510 Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study |
| title_full | 510 Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study |
| title_fullStr | 510 Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study |
| title_full_unstemmed | 510 Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study |
| title_short | 510 Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study |
| title_sort | 510 prevalence and clinical impact of respiratory viral infections in the standardized treatment of pulmonary exacerbations 2 study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527872/ http://dx.doi.org/10.1016/S1569-1993(22)01200-0 |
| work_keys_str_mv | AT thorntonc 510prevalenceandclinicalimpactofrespiratoryviralinfectionsinthestandardizedtreatmentofpulmonaryexacerbations2study AT kalikinl 510prevalenceandclinicalimpactofrespiratoryviralinfectionsinthestandardizedtreatmentofpulmonaryexacerbations2study AT sandersd 510prevalenceandclinicalimpactofrespiratoryviralinfectionsinthestandardizedtreatmentofpulmonaryexacerbations2study AT mcclellans 510prevalenceandclinicalimpactofrespiratoryviralinfectionsinthestandardizedtreatmentofpulmonaryexacerbations2study AT lebarw 510prevalenceandclinicalimpactofrespiratoryviralinfectionsinthestandardizedtreatmentofpulmonaryexacerbations2study AT vandevanterd 510prevalenceandclinicalimpactofrespiratoryviralinfectionsinthestandardizedtreatmentofpulmonaryexacerbations2study AT heltshes 510prevalenceandclinicalimpactofrespiratoryviralinfectionsinthestandardizedtreatmentofpulmonaryexacerbations2study AT caverlyl 510prevalenceandclinicalimpactofrespiratoryviralinfectionsinthestandardizedtreatmentofpulmonaryexacerbations2study AT lipumaj 510prevalenceandclinicalimpactofrespiratoryviralinfectionsinthestandardizedtreatmentofpulmonaryexacerbations2study |